Oppenheimer & Co. Inc. Expands Biotech Research Team
The addition of a well-respected biotech expert enhances Oppenheimer's commitment to innovation and excellence.
Oppenheimer & Co. Inc., a prominent investment bank and wealth manager, has recently fortified its Biotech Research Team with the addition of Kostas Biliouris as a Managing Director. Reporting directly to Bill Bird, the firm’s Director of Research, Kostas will play a critical role in advancing the firm's capabilities in the dynamic biotech sector.
Before joining Oppenheimer, Biliouris held a Director position at BMO Capital Markets, focusing primarily on the burgeoning field of genetic medicines. With a robust background that includes serving as a VP in Biotech Research at Morgan Stanley and experience in drug development at Novartis, he is bringing invaluable expertise to Oppenheimer. His impressive credentials are bolstered by a Ph.D. in biochemical engineering and publication collaborations with industry leaders such as Biogen, Ionis, Merck, and Novartis.
Bill Bird expressed enthusiasm over Biliouris's arrival, stating, "Kostas brings a rare combination of scientific depth, industry experience, and securities analysis that fits directly into our approach to biotech equity research. His commercial mindset has been shaped by years of engagement with investors and corporate leaders, making him highly regarded by institutional and corporate clients. We are excited about the expansion of our biotech research coverage, which is an area of rapid innovation and growing client interest. Kostas brings extraordinary experience and perspective, and we are thrilled to have him on board."
Oppenheimer's commitment to healthcare extends across the entire ecosystem, spanning biotechnology, pharmaceuticals, medical technology, and various related sectors. The firm has established itself as a significant player within the healthcare investment landscape.
Insights from the New Managing Director
Biliouris shared his excitement about joining Oppenheimer's renowned research team, expressing anticipation for the opportunity to contribute to a platform known for its commitment to healthcare and thoughtful industry coverage. He noted, "The pace of innovation in genetic medicines and the broader biotech space continues to accelerate, and I look forward to collaborating with my colleagues to make sense of these developments for our clients." His passion for the industry and desire to provide insightful research promises to enrich Oppenheimer’s overall offerings in biotech.
Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary, offers a comprehensive range of wealth management, securities brokerage, and investment banking services tailored for high-net-worth individuals, families, corporate executives, businesses, and institutions. This strategic addition to their team reinforces their dedication to delivering high-quality insights and support across the healthcare sector.
Media Contact:
Michael Dugan
Haven Tower Group LLC
424 317 4852
Frequently Asked Questions
What is the role of Kostas Biliouris at Oppenheimer?
Kostas Biliouris has been appointed as a Managing Director in the Biotech Research Team at Oppenheimer, where he will enhance the firm's research capabilities.
What is Oppenheimer's focus in the healthcare sector?
Oppenheimer focuses on biotechnology, pharmaceuticals, and medical technology, providing insights and coverage across the entire healthcare ecosystem.
Where did Kostas Biliouris work before joining Oppenheimer?
Before Oppenheimer, Kostas Biliouris worked at BMO Capital Markets and Morgan Stanley, with extensive experience in the biotech field.
What is Oppenheimer's approach to investment banking?
Oppenheimer aims to provide insightful research and comprehensive services, catering to high-net-worth individuals and institutions through its wealth management and investment banking divisions.
How does Kostas Biliouris enhance Oppenheimer's research capabilities?
Kostas Biliouris brings a blend of scientific expertise and industry experience, which will help strengthen Oppenheimer's biotech equity research efforts.
